Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2003-11-03
2009-11-17
Sheikh, Humera N (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S464000, C424S465000, C424S468000, C424S472000
Reexamination Certificate
active
07618649
ABSTRACT:
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4731447 (1988-03-01), Schumacher et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4804666 (1989-02-01), Piwinski et al.
patent: 4863931 (1989-09-01), Schumacher et al.
patent: 4906647 (1990-03-01), Kouchiwa et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5476856 (1995-12-01), Carceller et al.
patent: 5487901 (1996-01-01), Conte et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 5939426 (1999-08-01), McCullough
patent: 5997903 (1999-12-01), Dietrich et al.
patent: 6051585 (2000-04-01), Weinstein et al.
patent: 6100274 (2000-08-01), Kou
patent: 6114346 (2000-09-01), Harris et al.
patent: 6132758 (2000-10-01), Munayyer et al.
patent: 6265414 (2001-07-01), Harris et al.
patent: 6270796 (2001-08-01), Weinstein et al.
patent: 6372802 (2002-04-01), Hellberg et al.
patent: 6423721 (2002-07-01), Harris et al.
patent: 6432972 (2002-08-01), Salmun et al.
patent: 6506767 (2003-01-01), Schumacher et al.
patent: 6514520 (2003-02-01), Munayyer et al.
patent: 6521254 (2003-02-01), Weinstein et al.
patent: 6709676 (2004-03-01), Cho
patent: 6979463 (2005-12-01), Kou
patent: 7211582 (2007-05-01), Aberg et al.
patent: 7214683 (2007-05-01), Aberg et al.
patent: 7214684 (2007-05-01), Aberg et al.
patent: 2002/0123504 (2002-09-01), Redmon et al.
patent: 2004/0097536 (2004-05-01), Cho
patent: 2006/0079489 (2006-04-01), Redmon et al.
patent: 0 264 259 (1988-04-01), None
patent: 0 288640 (1988-11-01), None
patent: 0173928 (1990-06-01), None
patent: 0 396404 (1990-11-01), None
patent: 0 577 957 (1994-01-01), None
patent: 0 396404 (1994-02-01), None
patent: 0655744 (2000-01-01), None
patent: 1112738 (2001-07-01), None
patent: WO 85/03707 (1985-08-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 92/11034 (1992-07-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO-94/09761 (1994-05-01), None
patent: WO 96/16641 (1996-06-01), None
patent: WO 96/20708 (1996-07-01), None
patent: WO 98/34614 (1998-08-01), None
patent: WO 00/02560 (2000-01-01), None
Andersen, et al., “Adverse drug interactions clinically important for the dermatologist”, Arch Dermatol, Apr. 1995, vol. 131, pp. 468-473.
Babe, et al., “Histamine, Bradykinn, and their Antagonists” in The Pharmacological Basis of Therapeutics (9thedition), The McGraw-Hill Co. Inc., pp. 581-599 (1996).
Barnett, et al.,“Pharmacology of Non-Sedating H1 Antihistamines”,New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991).
Berge, et al., “Pharmaceutical Salts”, J. of Pharm. Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)”, Biochem. Pharm., 1994, vol. 47, No. 5, pp. 789-794.
Blaug, et al., “Interaction of dextroamphetamine sulfate with spray-dried lactose”, J. of Pharm. Sciences, Nov. 1972, vol. 61, No. 11, pp. 1770-1775.
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates”, J. of the National Cancer Inst., May 18, 1994, vol. 86, No. 10, pp. 770-775.
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses”, Cancer Research, Jul. 1, 1992, vol. 52, pp. 3796-3800.
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers”, Br. J. Clin. Pharmac. 1988, vol. 25, pp. 27-32.
Carmeliet, “Voltage- and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes by Dofetilide”, The J. of Pharm. And Experimental Therapeutics, 1992, vol. 262, No. 2, pp. 809-817.
Castello, et al., “Discoloration of tablets containing amines and lactose”, J. of Pharm. Sciences, Feb. 1962,vol. 51, No. 2, pp. 106-108.
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey”, J. Clin. Pharmacol, 1992, vol. No. 32, pp. 163-175.
Clissold, et al., “Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy”, Drugs, 1989,vol. 37, pp. 42-57.
Cooke, “Glycopyrrolate in bladder dysfunction”, SA Medical Journal, Jan. 1, 1983, p. 3.
Craft, “Torsade de pointes after astemizole overdose”, Br. Medical Journal, 1986,, vol. 292, p. 660.
Dorje, et al., “Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes”, The J. of Pharm. And Experimental Therapeutics, 1991, Vol. 256, pp. 727-733.
Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832.
Ebert, “Soft elastic gelatin capsules: a unique dosage form”, Pharmaceutical Technology, 1977, pp. 44-50.
Gengo, “Dilemma: Antihistamine selection: Use vs. Side effects”, U.S. Pharmacist, Nov. 1990, pp. 59-92.
Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, “Drug Development and industrial Pharmacy”, 1991, vol. 17, No. 4, pp. 617-630.
Herron, et al, “Dose Proportionality, Linearity, and Pharmacokiinetics of Desloratadine in Healthy Volunteers” (Abstract 1126), J. Allergy Clin. Immunol., Jan. 2000, vol. 105, No. 1, Part 2, p. S385.
Herzog, et al., “Urinary Incontinence: medical and Psychosocial Aspects”,Annual Review of Gerontology and Geriatrics, 1989, vol. 9, pp. 74-119.
Hilbert, et al., “Pharmacokinetics and Dose Proportionality of Loratadine”, J. Clin. Pharmacol. 1987, vol. 27, pp. 694-698.
Housley, et al., “Histamine and related substances influence neurotransmission in the semicircular canal”, Hearing Research, May 1, 1988, vol. 35, pp. 87-97.
Jankowski, et al., “Effect of Terfenadine on Nnasal Provocation”, Int. Arch. Allergy Immunolog., 1993, vol. 101, pp. 311-317.
Kaliner, “Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects”, American Family Physician, Mar. 1992, vol. 45, No. 3, pp. 1337-1342.
Kleine-Tebbe, et al., “Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine”, J. Allergy Clin. Immunol., 1994, vol. 93, pp. 494-500.
Knowles, “Astemizole and Terfenadine-Induced Cardiovascular E
Covington & Burling LLP
Schering Corporation
Sheikh Humera N
LandOfFree
Extended release oral dosage composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extended release oral dosage composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extended release oral dosage composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4128857